Brief: Heartbeam Provides Update On Regulatory Path Following FDA Decision On 12-Lead ECG Synthesis Software Application
26/11/2025 22:41
Nov 26 (Reuters) - Heartbeam Inc BEAT.O: HEARTBEAM PROVIDES UPDATE ON REGULATORY PATH FOLLOWING FDA DECISION ON 12-LEAD ECG SYNTHESIS SOFTWARE APPLICATION Source text: ID:nBw8fzlZ0a Further company coverage: BEAT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heartbeam
See all newsBrief: Heartbeam Announces Strategic Shift To Accelerate Global Adoption Of Its Ambulatory ECG Signal Platform And Leadership Transition
Brief: Heartbeam Reports First Quarter 2026 Results
HeartBeam Q1 net loss narrows as commercialization advances
Brief: Heartbeam Initiates Pilot Study Of First On-Demand 12-Lead ECG Patch To Detect Ischemia Outside The Clinic
Brief: Heartbeam Expands Commercial Presence Across Four Key U.S. Markets With Addition Of Premier Concierge Practice